|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
|
PT1107964E
(pt)
|
1998-08-11 |
2010-06-11 |
Novartis Ag |
Derivados de isoquinolina com actividade inibidora da angiogénese
|
|
US6133031A
(en)
|
1999-08-19 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of focal adhesion kinase expression
|
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
KR100786927B1
(ko)
|
2000-06-28 |
2007-12-17 |
스미스클라인비이참피이엘시이 |
습식 분쇄방법
|
|
BR0212760A
(pt)
|
2001-09-19 |
2004-12-07 |
Aventis Pharma Sa |
Compostos quìmicos
|
|
DE60213842T2
(de)
|
2001-10-30 |
2007-09-06 |
Novartis Ag |
Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
|
|
CA2466279A1
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
MXPA04005939A
(es)
|
2002-01-22 |
2005-01-25 |
Warner Lambert Co |
2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
|
|
PE20040522A1
(es)
|
2002-05-29 |
2004-09-28 |
Novartis Ag |
Derivados de diarilurea dependientes de la cinasa de proteina
|
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
|
TWI335913B
(en)
|
2002-11-15 |
2011-01-11 |
Vertex Pharma |
Diaminotriazoles useful as inhibitors of protein kinases
|
|
UA80767C2
(en)
|
2002-12-20 |
2007-10-25 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
GB0305929D0
(en)
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
|
JP2007504232A
(ja)
|
2003-09-05 |
2007-03-01 |
アナディス ファーマシューティカルズ インク |
Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
|
|
AR045944A1
(es)
|
2003-09-24 |
2005-11-16 |
Novartis Ag |
Derivados de isoquinolina 1.4-disustituidas
|
|
KR20070015598A
(ko)
|
2004-04-28 |
2007-02-05 |
다케다 야쿠힌 고교 가부시키가이샤 |
융합 퀴놀린 유도체 및 이의 용도
|
|
WO2006038923A2
(en)
|
2004-06-18 |
2006-04-13 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
|
WO2006029115A2
(en)
|
2004-09-02 |
2006-03-16 |
3M Innovative Properties Company |
2-amino 1h imidazo ring systems and methods
|
|
AU2005309019A1
(en)
|
2004-11-24 |
2006-06-01 |
Novartis Ag |
Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
|
|
EP1845988A2
(en)
|
2005-02-11 |
2007-10-24 |
3M Innovative Properties Company |
Substituted imidazoquinolines and imidazonaphthyridines
|
|
JP2008531567A
(ja)
|
2005-02-23 |
2008-08-14 |
コーリー ファーマシューティカル グループ，インコーポレイテッド |
ヒドロキシアルキル置換イミダゾキノリン化合物および方法
|
|
AU2006216686A1
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Method of preferentially inducing the biosynthesis of interferon
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
GB0522715D0
(en)
|
2005-11-08 |
2005-12-14 |
Helperby Therapeutics Ltd |
New use
|
|
GB0709513D0
(en)
|
2007-05-17 |
2007-06-27 |
Helperby Therapeutics Ltd |
Topical formulations
|
|
EP1972629A1
(en)
|
2007-03-23 |
2008-09-24 |
Mutabilis SA |
New imidazolo-heteroaryl derivatives with antibacterial properties
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
EA201001030A1
(ru)
|
2007-12-19 |
2011-02-28 |
Амген Инк. |
Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
US8436005B2
(en)
|
2008-04-03 |
2013-05-07 |
Abbott Laboratories |
Macrocyclic pyrimidine derivatives
|
|
AR073574A1
(es)
|
2008-09-10 |
2010-11-17 |
Alcon Res Ltd |
Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
JP2012506848A
(ja)
|
2008-10-27 |
2012-03-22 |
グラクソ グループ リミテッド |
グルタミン酸受容体モジュレーターとしての三環式化合物
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
PA8852901A1
(es)
|
2008-12-22 |
2010-07-27 |
Lilly Co Eli |
Inhibidores de proteina cinasa
|
|
JP5844159B2
(ja)
|
2009-02-09 |
2016-01-13 |
ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ |
Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
|
|
US20100298302A1
(en)
|
2009-05-20 |
2010-11-25 |
Fabrice Pierre |
Novel protein kinase modulators
|
|
AU2009349135A1
(en)
|
2009-06-30 |
2012-02-16 |
Piramal Enterprises Limited |
Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation
|
|
JP2013504325A
(ja)
|
2009-09-09 |
2013-02-07 |
アビラ セラピューティクス， インコーポレイテッド |
Ｐｉ３キナーゼインヒビターおよびその使用
|
|
GB0919423D0
(en)
*
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
WO2011082400A2
(en)
|
2010-01-04 |
2011-07-07 |
President And Fellows Of Harvard College |
Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
WO2011144622A1
(en)
|
2010-05-17 |
2011-11-24 |
Boehringer Ingelheim International Gmbh |
1h - imidazo [4, 5 - c] quinolines
|
|
WO2011159877A2
(en)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
MX2013000617A
(es)
|
2010-07-16 |
2013-06-13 |
Piramal Entpr Ltd |
Derivados sustituidos de imidazoquinolina como inhibidores de quinasa.
|
|
WO2012011642A1
(ko)
|
2010-07-23 |
2012-01-26 |
고려대학교 산학협력단 |
염료감응 태양전지용 준고체 고분자 전해질, 그에 포함되는 정공수송물질, 및 그 전해질을 포함하는 염료감응 태양전지
|
|
CN102399218A
(zh)
|
2010-09-16 |
2012-04-04 |
和记黄埔医药（上海）有限公司 |
一类并合三杂环及其作为pi3k抑制剂的用途
|
|
MX338327B
(es)
|
2010-10-25 |
2016-04-12 |
G1 Therapeutics Inc |
Inhibidores de cdk.
|
|
EP2937349B1
(en)
|
2011-03-23 |
2016-12-28 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
|
WO2012154731A1
(en)
|
2011-05-08 |
2012-11-15 |
Vanderbilt University |
Substituted 1h-pyrrolo[3,2-c]quinolin-4(5h)-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
|
|
WO2013033268A2
(en)
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Bivalent bromodomain ligands, and methods of using same
|
|
CN103012397B
(zh)
|
2011-09-26 |
2017-03-01 |
赛诺菲 |
吡唑并喹啉酮衍生物、其制备方法及其治疗用途
|
|
US9169246B2
(en)
|
2011-09-26 |
2015-10-27 |
Sanofi |
Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
|
|
SI2573073T1
(sl)
|
2011-09-26 |
2015-02-27 |
Sanofi |
Pirazolokinolinonski derivati, njihova priprava in njihova terapevtska uporaba
|
|
CA2850932A1
(en)
|
2011-10-04 |
2013-04-11 |
Janus Biotherapeutics, Inc. |
Novel imidazole quinoline-based immune system modulators
|
|
JO3116B1
(ar)
|
2011-10-07 |
2017-09-20 |
Eisai R&D Man Co Ltd |
مشتق بيرازولوكينولين كمثبطات ل pde9
|
|
EP2968285A4
(en)
|
2013-03-13 |
2016-12-21 |
Flatley Discovery Lab |
COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
|
|
JP6244353B2
(ja)
|
2013-04-05 |
2017-12-06 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ピリジニルピラゾロキノリン化合物
|
|
US9573947B2
(en)
|
2013-04-05 |
2017-02-21 |
Eisai R&D Management Co., Ltd. |
Salt of pyrazoloquinoline derivative, and crystal thereof
|
|
WO2015073804A2
(en)
|
2013-11-15 |
2015-05-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method of blocking transmission of malarial parasite
|
|
WO2016141296A1
(en)
|
2015-03-04 |
2016-09-09 |
Dana-Farber Caner Institute, Inc. |
Tricyclic kinase inhibitors of melk and methods of use
|
|
EP3277678B1
(en)
|
2015-04-03 |
2020-03-18 |
NantBio, Inc. |
Compositions and methods of targeting mutant k-ras
|
|
US10428064B2
(en)
|
2015-04-15 |
2019-10-01 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of KRAS and methods of use thereof
|
|
WO2016199943A1
(en)
|
2015-06-11 |
2016-12-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compounds
|
|
HUE068868T2
(hu)
|
2015-07-30 |
2025-02-28 |
Macrogenics Inc |
PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
|
|
RU2722149C1
(ru)
|
2015-09-14 |
2020-05-27 |
Пфайзер Инк. |
Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
|
|
WO2017058805A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017070089A1
(en)
|
2015-10-19 |
2017-04-27 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
SG10202004618TA
(en)
|
2015-11-19 |
2020-06-29 |
Incyte Corp |
Heterocyclic compounds as immunomodulators
|
|
CN113912648A
(zh)
|
2015-12-02 |
2022-01-11 |
深圳市塔吉瑞生物医药有限公司 |
一种二氨基嘧啶化合物及包含该化合物的组合物
|
|
MA44075A
(fr)
|
2015-12-17 |
2021-05-19 |
Incyte Corp |
Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
|
|
AU2016379372A1
(en)
|
2015-12-22 |
2018-08-02 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
US10730871B2
(en)
|
2016-01-28 |
2020-08-04 |
Regents Of The University Of Minnesota |
Immunomodulators and immunomodulator conjugates
|
|
KR102606277B1
(ko)
|
2016-04-06 |
2023-11-27 |
삼성디스플레이 주식회사 |
유기 발광 소자
|
|
AR108396A1
(es)
|
2016-05-06 |
2018-08-15 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
|
KR102444509B1
(ko)
|
2016-05-18 |
2022-09-19 |
미라티 테라퓨틱스, 인크. |
Kras g12c 억제제
|
|
WO2017205464A1
(en)
|
2016-05-26 |
2017-11-30 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
HUE060256T2
(hu)
|
2016-06-20 |
2023-02-28 |
Incyte Corp |
Heterociklusos vegyületek mint immunmodulátorok
|
|
EP3484866B1
(en)
|
2016-07-14 |
2022-09-07 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
WO2018044783A1
(en)
|
2016-08-29 |
2018-03-08 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
LT3558990T
(lt)
|
2016-12-22 |
2022-12-27 |
Incyte Corporation |
Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai
|
|
JP7101678B2
(ja)
|
2016-12-22 |
2022-07-15 |
インサイト・コーポレイション |
免疫調節剤としての複素環式化合物
|
|
US20180179202A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
CN110366550A
(zh)
|
2016-12-22 |
2019-10-22 |
美国安进公司 |
作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
|
|
ES2874756T3
(es)
|
2016-12-22 |
2021-11-05 |
Incyte Corp |
Derivados de triazolo[1,5-A]piridina como inmunomoduladores
|
|
WO2018119221A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Pyridine derivatives as immunomodulators
|
|
WO2018119263A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds derivatives as pd-l1 internalization inducers
|
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
AU2018273356B2
(en)
|
2017-05-22 |
2021-09-16 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
LT3710439T
(lt)
|
2017-11-15 |
2023-05-10 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitoriai
|
|
CN108003153B
(zh)
|
2017-11-24 |
2021-04-30 |
中国医学科学院肿瘤医院 |
含氮五元杂环并喹啉类化合物及其盐、制法、药物组合物和用途
|
|
US10597405B2
(en)
|
2017-12-08 |
2020-03-24 |
Astrazeneca Ab |
Chemical compounds
|
|
SMT202500157T1
(it)
|
2018-03-30 |
2025-05-12 |
Incyte Corp |
Composti eterociclici come immunomodulatori
|
|
WO2019201283A1
(en)
|
2018-04-20 |
2019-10-24 |
Xrad Therapeutics, Inc. |
Dual atm and dna-pk inhibitors for use in anti-tumor therapy
|
|
PE20210160A1
(es)
|
2018-04-25 |
2021-01-26 |
Innate Tumor Immunity Inc |
Moduladores de nlrp3
|
|
CA3098574A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
HUE061503T2
(hu)
|
2018-05-11 |
2023-07-28 |
Incyte Corp |
Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok
|
|
WO2020037091A1
(en)
|
2018-08-16 |
2020-02-20 |
Innate Tumor Immunity, Inc. |
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
|
ES2974964T3
(es)
|
2018-08-16 |
2024-07-02 |
Innate Tumor Immunity Inc |
Moduladores de NLRP3 derivados de imidazo[4,5-c]quinolina
|
|
ES3017461T3
(en)
|
2018-09-10 |
2025-05-13 |
Mirati Therapeutics Inc |
Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
|
|
WO2021150613A1
(en)
|
2020-01-20 |
2021-07-29 |
Incyte Corporation |
Spiro compounds as inhibitors of kras
|
|
AU2021254794A1
(en)
|
2020-04-16 |
2022-12-15 |
Incyte Corporation |
Fused tricyclic KRAS inhibitors
|
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
|
US11999752B2
(en)
|
2020-08-28 |
2024-06-04 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of KRAS
|